31 January 2019 - Italfarmaco strengthen its presence in rare disease area by launching the medicinal product VOTUBIA
VOTUBIA (everolimus, 2 mg and 3 mg dispersible tablets for oral use) is a prescription medicine approved for the treatment of a brain tumour, the subependymal giant cell astrocytoma (SEGA) associated to the genetic disease called “Tuberous Sclerosis Complex (TSC)”. The treatment is indicated in adult and pediatric patients that require a therapeutic intervention but cannot be curatively resected.
VOTUBIA is also approved as add-on treatment in patients aged 2 years and older with seizures related to TSC that have not responded to other treatments. VOTUBIA is the first approved and reimbursed medicine available in Italy for the treatment of two of the most important disease manifestations of Tuberous Sclerosis. The medicine acts by selectively blocking an enzyme pathway called mTOR, which has increased its activity as a result of the gene mutation behind the disease. Tuberous Sclerosis is a rare disease and VOTUBIA has been designated an “orphan drug” on August 2010.